Cargando…

Continuous vs bolus administration of imipenem in critically ill patients with ICU-acquired pneumonia

Detalles Bibliográficos
Autores principales:	Sakka, S, Glauner, A, Bulitta, J, Kinzig-Schippers, M, Sörgel, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099820/ http://dx.doi.org/10.1186/cc2700

Ejemplares similares

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
por: Mashaly, Mervat El-Sayed, et al.
Publicado: (2021)

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
por: Sörgel, Fritz, et al.
Publicado: (2009)

Community-acquired pneumonia treated on the ICU
por: Apostolidou, E, et al.
Publicado: (2006)

Continuous infusion versus intermittent bolus of ceftazidime for the treatment of nosocomial pneumonia
por: Lorente, L, et al.
Publicado: (2003)

Updates on community acquired pneumonia management in the ICU
por: Nair, Girish B., et al.
Publicado: (2021)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
por: Patel, Munjal, et al.
Publicado: (2021)

Continuous versus bolus furosemide therapy in critically ill patients with fluid overload
por: Ostermann, M, et al.
Publicado: (2002)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Bolus or continuous hydrocortisone – that is the question
por: Weber-Carstens, Steffen, et al.
Publicado: (2007)

No Development of Imipenem Resistance in Pneumonia Caused by Escherichia coli
por: Yayan, Josef, et al.
Publicado: (2015)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Comparison of the effects of enteral feeding through the bolus and continuous methods on blood sugar and prealbumin levels in ICU inpatients
por: Shahriari, Mohsen, et al.
Publicado: (2015)

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
por: Motsch, Johann, et al.
Publicado: (2020)

ICU admission and severity assessment in community-acquired pneumonia
por: Chalmers, James D
Publicado: (2009)

What is new in non-ventilated ICU-acquired pneumonia?
por: Saied, Wafa Ibn, et al.
Publicado: (2020)

Caffeine, Paraxanthine, Theophylline, and Theobromine Content in Human Milk
por: Purkiewicz, Aleksandra, et al.
Publicado: (2022)

Early use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trial
por: Kim, Jong Wook, et al.
Publicado: (2012)

Incidence of imipenem-resistant Acinetobacter baumannii in a general intensive care unit (ICU)
por: Alavi-Moghadam, Mostafa, et al.
Publicado: (2014)

Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials
por: Falagas, Matthew E, et al.
Publicado: (2006)

Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review
por: Zilberberg, Marya D, et al.
Publicado: (2010)

In vivo Selection of Imipenem Resistance Among Ceftazidime-Avibactam-Resistant, Imipenem-Susceptible Klebsiella pneumoniae Isolate With KPC-33 Carbapenemase
por: Wang, Chunlei, et al.
Publicado: (2021)

Comparison between continuous versus bolus furosemide administration in oliguric postoperative paediatric cardiac patients
por: Taylor, D, et al.
Publicado: (2003)

Effect of Bolus Insulin Administration Followed by a Continuous Insulin Infusion on Diabetic Ketoacidosis Management
por: Brown, Hannah D., et al.
Publicado: (2018)

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding
por: Shah, Nirav R., et al.
Publicado: (2019)

SARS-CoV-2 viral load dynamics in immunocompromised critically ill patients on remdesivir treatment
por: Lahmer, Tobias, et al.
Publicado: (2022)

2197. Ceftriaxone Monotherapy vs. Ceftriaxone Plus Azithromycin for the Treatment of Community-Acquired Pneumonia in Hospitalized, Non-ICU Patients
por: Murter, Forrest, et al.
Publicado: (2019)

Pharmacokinetics Alterations of Midazolam Infusion versus Bolus Administration in Mechanically Ventilated Critically Ill Patients
por: Beigmohammadi, Mohammad Taghi, et al.
Publicado: (2013)

1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
por: Chen, Luke F, et al.
Publicado: (2020)

Validation of predictive rules for ICU patients with community-acquired pneumonia
por: Rudnov, V, et al.
Publicado: (2008)

Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia
por: Ceccato, Adrian, et al.
Publicado: (2019)

Clonal Relatedness among Imipenem-Resistant Pseudomonas aeruginosa Isolated from ICU-Hospitalized Patients
por: Vaez, Hamid, et al.
Publicado: (2015)

Penetration of Isavuconazole in Ascites Fluid of Critically Ill Patients
por: Lahmer, Tobias, et al.
Publicado: (2021)

Epidemiology and resistance mechanisms to imipenem in Klebsiella pneumoniae: A multicenter study
por: CHEN, HUIHONG, et al.
Publicado: (2013)

Hyperglycemia Risk Evaluation of Hydrocortisone Intermittent Boluses vs Continuous Infusion in Septic Shock: A Retrospective Study
por: Mitwally, Hassan, et al.
Publicado: (2021)

ICU-acquired bloodstream infections in critically ill patients with COVID-19()
por: Kokkoris, S., et al.
Publicado: (2021)

Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in ICU: an open randomised multicentre study
por: Verwaest on behalf of the Belgiun Multicentre study group, C
Publicado: (1997)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
por: Jang, Soo Min, et al.
Publicado: (2021)

Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU
por: Belkhouja, Khairallah, et al.
Publicado: (2011)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i46roh30g3sela68jinouqrcb1